-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on WAVE Life Sciences, Raises Price Target to $35

Benzinga·03/06/2026 13:56:46
Listen to the news
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises the price target from $33 to $35.